Alnylam PharmaceuticalsALNY
About: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Employees: 2,230
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
49% more first-time investments, than exits
New positions opened: 88 | Existing positions closed: 59
33% more repeat investments, than reductions
Existing positions increased: 229 | Existing positions reduced: 172
17% more call options, than puts
Call options by funds: $195M | Put options by funds: $166M
2.38% more ownership
Funds ownership: 96.36% [Q3] → 98.74% (+2.38%) [Q4]
1% more funds holding
Funds holding: 556 [Q3] → 560 (+4) [Q4]
12% less capital invested
Capital invested by funds: $34B [Q3] → $30B (-$4.06B) [Q4]
43% less funds holding in top 10
Funds holding in top 10: 7 [Q3] → 4 (-3) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Canaccord Genuity Whitney Ijem 22% 1-year accuracy 9 / 41 met price target | 54%upside $385 | Buy Maintained | 18 Feb 2025 |
Scotiabank Greg Harrison 39% 1-year accuracy 13 / 33 met price target | 20%upside $300 | Sector Outperform Maintained | 14 Feb 2025 |
Morgan Stanley Michael Ulz 19% 1-year accuracy 3 / 16 met price target | 13%upside $284 | Equal-Weight Maintained | 14 Feb 2025 |
Needham Joseph Stringer 22% 1-year accuracy 27 / 124 met price target | 28%upside $320 | Buy Reiterated | 14 Feb 2025 |
RBC Capital Luca Issi 21% 1-year accuracy 12 / 56 met price target | 20%upside $300 | Outperform Reiterated | 11 Feb 2025 |
Financial journalist opinion
Based on 16 articles about ALNY published over the past 30 days
